EA201991448A1 - AZEPAN INTERACTION INHIBITORS MENIN-MLL - Google Patents

AZEPAN INTERACTION INHIBITORS MENIN-MLL

Info

Publication number
EA201991448A1
EA201991448A1 EA201991448A EA201991448A EA201991448A1 EA 201991448 A1 EA201991448 A1 EA 201991448A1 EA 201991448 A EA201991448 A EA 201991448A EA 201991448 A EA201991448 A EA 201991448A EA 201991448 A1 EA201991448 A1 EA 201991448A1
Authority
EA
Eurasian Patent Office
Prior art keywords
menin
mll
azepan
interaction inhibitors
compounds
Prior art date
Application number
EA201991448A
Other languages
Russian (ru)
Inventor
Патрик Рене Анжибо
Винет Панде
Барбара Херкерт
Дэниел Джейсон Кроски
Оливье Алексис Жорж Керолль
Аарон Натаниэль Патрик
Изабелль Ноэлль Констанс Пилатт
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201991448A1 publication Critical patent/EA201991448A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к фармацевтическим средствам, пригодным для терапии и/или профилактики у млекопитающего, и, в частности, к азепановым соединениям, фармацевтической композиции, содержащей такие соединения, и к их применению в качестве ингибиторов белок-белковых взаимодействий менин-MLL, пригодных для лечения заболеваний, таких как рак, миелодиспластический синдром (MDS) и диабет.The invention relates to pharmaceuticals suitable for the treatment and / or prophylaxis in a mammal, and in particular to azepane compounds, a pharmaceutical composition containing such compounds, and their use as menin-MLL protein-protein interactions inhibitors suitable for treatment diseases such as cancer, myelodysplastic syndrome (MDS), and diabetes.

EA201991448A 2017-01-06 2017-12-14 AZEPAN INTERACTION INHIBITORS MENIN-MLL EA201991448A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17150502 2017-01-06
PCT/EP2017/082826 WO2018109088A1 (en) 2016-12-15 2017-12-14 Azepane inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
EA201991448A1 true EA201991448A1 (en) 2019-12-30

Family

ID=57749853

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991448A EA201991448A1 (en) 2017-01-06 2017-12-14 AZEPAN INTERACTION INHIBITORS MENIN-MLL

Country Status (2)

Country Link
EA (1) EA201991448A1 (en)
WO (1) WO2018109088A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019004691A2 (en) 2016-09-14 2019-06-25 Janssen Pharmaceutica Nv spiro bicyclic inhibitors of girl-mll interaction
EP3512858B1 (en) 2016-09-14 2023-11-08 Janssen Pharmaceutica NV Fused bicyclic inhibitors of menin-mll interaction
KR102513564B1 (en) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. An azepane inhibitor of the menin-MLL interaction
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
BR112021007421A2 (en) 2018-12-06 2021-08-03 Daiichi Sankyo Company, Limited cycloalkane-1,3-diamine derivative
KR20240005747A (en) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 Substituted Spiro Derivatives
KR20240006542A (en) 2021-05-08 2024-01-15 얀센 파마슈티카 엔브이 Substituted Spiro Derivatives
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
EP4347600A1 (en) 2021-06-03 2024-04-10 JANSSEN Pharmaceutica NV Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
EP4355747A1 (en) 2021-06-17 2024-04-24 JANSSEN Pharmaceutica NV (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2015191701A1 (en) * 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2016081732A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AR104020A1 (en) 2015-06-04 2017-06-21 Kura Oncology Inc METHODS AND COMPOSITIONS TO INHIBIT THE INTERACTION OF MENINA WITH MILL PROTEINS
BR112018012707A2 (en) 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc menin-mll interaction inhibitors
DK3429591T3 (en) 2016-03-16 2023-06-19 Kura Oncology Inc Substituted thieno[2,3-D]pyrimidine derivatives as inhibitors of Menin-MLL and methods of use
AU2017235462B2 (en) 2016-03-16 2021-07-01 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use

Also Published As

Publication number Publication date
WO2018109088A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
EA201991448A1 (en) AZEPAN INTERACTION INHIBITORS MENIN-MLL
EA201990699A1 (en) SPIROBICYCLIC INhibitors of the MENIN – MLL INTERACTION
MX2019002959A (en) Fused bicyclic inhibitors of menin-mll interaction.
EA201891489A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AMORPHOUS LENALIDOMIDE AND ANTIOXIDANT
EA201891344A1 (en) NEW APONEL RECEPTOR AGONISTS AND APPLICATION METHODS
CL2016002900A1 (en) Compound 1 - ((3s, 4r) -4- (3-fluorophenyl) -1- (2-methoxyethyl) pyrrolidin-3-ll) -3- (4-methyl-3- (2- methylpyrimidin-5-yl) -1-phenyl-1h-pyrazol-5-yl) urea, trka kinase inhibitor; process to prepare it; pharmaceutical composition comprising it; and use to treat pain, cancer, inflammation, neurodegenerative diseases, among others.
EA201691059A1 (en) PEPTIDOMYMETICS COMPOUNDS AND THEIR CONJUGATES CONTAINING ANTIBODY AND MEDICINE
EA201892123A1 (en) 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDIN-5-CARBOXAMIDE AS APJ AGONISTS
EA201891336A1 (en) Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
CL2015002767A1 (en) Therapeutic compounds and compositions
EA201690159A1 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
MX2019002962A (en) Spiro bicyclic inhibitors of menin-mll interaction.
CL2016000117A1 (en) Autotaxin inhibitors comprise a heteroaromatic ring-benzylamine basic cycle
UA116648C2 (en) FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES
EA201501032A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND ITS APPLICATIONS
CL2012000092A1 (en) Compounds derived from pyridine and pyrazine or a salt thereof, modulators of cdk9 protein kinase; Pharmaceutical composition that comprises them, useful for the treatment of cancer, cardiac hypotrophy, HIV and inflammatory diseases.
MX2020006594A (en) Exo-aza spiro inhibitors of menin-mll interaction.
EA202090098A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
CL2008000202A1 (en) Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain.
TR201908265T4 (en) Fused 1,4-dihydrodioxine derivatives as inhibitors of heat shock transcription factor 1.
BR112017005242A2 (en) compound, pharmaceutical composition, and compound for use.
EA201692008A1 (en) SUBSTITUTED CONDENSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
EA201690783A1 (en) SUBSTANCES, PHARMACEUTICAL COMPOSITION AND METHODS OF APPLICATION IN THE TREATMENT OF INFLAMMATORY DISEASES
EA201790349A1 (en) 6-ALKINYL-PYRIDINE DERIVATIVES AS SMAC MIMETIC PROTEINS
EA201890534A1 (en) NEW ANNELED PHENOXYCETAMIDES